IGM Biosciences (IGMS) Stock Price, News & Analysis

Company Overview

IGM Biosciences, Inc. is a clinical-stage biotechnology company pioneering a novel class of immunotherapies based on immunoglobulin M (IgM) antibody platforms. The company’s proprietary technology is designed to harness the unique properties of pentameric IgM antibodies, which enable potent tumor cell binding, efficient activation of the complement cascade and recruitment of immune effector cells. By focusing on the early phases of antibody engagement, IGM Biosciences aims to deliver differentiated therapeutic profiles compared with conventional IgG-based approaches.

The company’s pipeline includes multiple investigational candidates targeting both hematologic malignancies and solid tumors. Lead programs such as IGM‐2323 in non-Hodgkin lymphoma and IGM‐2644 in prostate cancer leverage the high avidity and multivalent binding of IgM molecules to drive enhanced tumor cell killing. Additional assets, like IGM-8444, are designed to engage death receptor pathways on tumor cells, underlining IGM’s strategy of exploring diverse mechanisms of action within its IgM platform.

Founded in 2014 and headquartered in Carlsbad, California, IGM Biosciences operates research, development and manufacturing facilities in the United States, with collaborations and clinical trial sites extending into Europe and Asia. The company has established partnerships with academic institutions and pharmaceutical organizations to advance its pipeline and validate its platform across multiple therapeutic areas. This global footprint supports both early-stage research and late-stage clinical execution.

IGM Biosciences is led by Amir Nashat, President and Chief Executive Officer, supported by a leadership team of industry veterans spanning research, clinical development and commercial operations. Leveraging decades of collective experience in antibody engineering, oncology drug development and regulatory strategy, the management group is committed to translating the company’s IgM platform into potential treatment options for patients with high‐unmet-need diseases.

Key Stats

• Today's Range: $1.26 to $1.28
• 50-Day Range: $1.08 to $1.36
• 52-Week Range: $0.92 to $22.50
• Volume: 201,553 shs
• Average Volume: 378,170 shs
• Market Capitalization: $76.22 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.50
• Consensus Rating: Reduce

IGM Biosciences Stock Analysis - MarketRank™

IGM Biosciences scored higher than 91% of companies evaluated by MarketBeat, and ranked 92nd out of 917 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Reduce

Consensus Rating

IGM Biosciences has received a consensus rating of Reduce. The company's average rating score is 1.90, and is based on no buy ratings, 9 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

IGM Biosciences has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for IGM Biosciences are expected to grow in the coming year, from ($3.35) to ($0.96) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of IGM Biosciences is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of IGM Biosciences is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

IGM Biosciences has a P/B Ratio of 1.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.36% of the float of IGM Biosciences has been sold short.

Short Interest Ratio / Days to Cover

IGM Biosciences has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IGM Biosciences has recently decreased by 45.42%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IGM Biosciences does not currently pay a dividend.

Dividend Growth

IGM Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -1.08

Percentage of Shares Shorted

2.36% of the float of IGM Biosciences has been sold short.

Short Interest Ratio / Days to Cover

IGM Biosciences has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IGM Biosciences has recently decreased by 45.42%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.97

News Sentiment

IGM Biosciences has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for IGM Biosciences this week, compared to 2 articles on an average week.

MarketBeat Follows

1 people have added IGM Biosciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, IGM Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,377.00 in company stock.

Percentage Held by Insiders

57.00% of the stock of IGM Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

42.79% of the stock of IGM Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IGMS Stock Analysis - Frequently Asked Questions

How have IGMS shares performed this year?

IGM Biosciences' stock was trading at $6.11 at the start of the year. Since then, IGMS shares have decreased by 79.1% and is now trading at $1.2750.

How were IGM Biosciences' earnings last quarter?

IGM Biosciences, Inc. (NASDAQ:IGMS) announced its earnings results on Tuesday, May, 13th. The company reported ($0.86) EPS for the quarter, missing analysts' consensus estimates of ($0.41) by $0.45. The business had revenue of $0.50 million for the quarter, compared to analysts' expectations of $4.25 million. IGM Biosciences had a negative net margin of 7,417.79% and a negative trailing twelve-month return on equity of 317.97%.

When did IGM Biosciences IPO?

IGM Biosciences (IGMS) raised $125 million in an initial public offering on Wednesday, September 18th 2019. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Jefferies, Piper Jaffray, Stifel and Guggenheim Securities served as the underwriters for the IPO.

How do I buy shares of IGM Biosciences?

Shares of IGMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of IGM Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that IGM Biosciences investors own include American Water Works (AWK), Waste Connections (WCN), Humana (HUM), The RMR Group (RMR), DiamondRock Hospitality (DRH), AU Optronics (AUOTY) and Voyager Therapeutics (VYGR).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/22/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IGMS
• CIK: 1496323
• Web: igmbio.com
• Phone: 650-965-7873
• Fax: N/A
• Employees: 190
• Year Founded: 2010

Price Target and Rating

• Average Price Target for IGM Biosciences: $5.50
• High Price Target: $20.00
• Low Price Target: $1.50
• Potential Upside/Downside: +331.4%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.90
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.27)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$195.79 million
• Net Margins: -7,417.79%
• Pretax Margin: -7,417.79%
• Return on Equity: -317.97%
• Return on Assets: -71.43%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.71
• Quick Ratio: 5.71

Sales & Book Value

• Annual Sales: $2.68 million
• Price / Sales: 28.44
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.82 per share
• Price / Book: 1.55

Miscellaneous

• Outstanding Shares: 59,780,000
• Free Float: 25,703,000
• Market Cap: $76.22 million
• Optionable: Optionable
• Beta: 0.48